FDA Withholds Approval: Phase 3 Psilocybin, MDMA Trials in US Psychiatry

Landmark Phase 3 Trials: Psilocybin and MDMA Reach New Milestones

Recent phase 3 clinical trials have brought psychedelic-assisted therapies to the forefront of psychiatric research, with psilocybin and MDMA (3,4-methylenedioxymethamphetamine) showing notable efficacy signals in major depressive disorder and post-traumatic stress disorder (PTSD), respectively. In 2025 and 2026, two phase 3 trials of COMP360, a synthetic psilocybin formulation, met their primary endpoints, marking the most advanced regulatory evidence for psychedelics to date. Meanwhile, MDMA-assisted psychotherapy amassed the largest phase 3 dataset ever for PTSD, with results published in 2024. These achievements represent a significant evolution from the field’s theoretical roots and subcultural associations to mainstream, data-driven clinical science.

Mechanisms, Methodology, and Regulatory Context

The US Food and Drug Administration (FDA) declined to approve MDMA-assisted psychotherapy for PTSD in 2024, citing ethical and methodological concerns despite promising efficacy data. The FDA’s decision (see FDA briefing document, 2024) highlights challenges unique to psychedelic trials: practical unblinding (where participants can often tell if they received the active drug), small sample sizes, and trial heterogeneity. Psilocybin trials, while achieving statistical significance in recent studies, have also faced scrutiny over these same methodological weaknesses. The international evidence grading system continues to rate the certainty of evidence for both substances as low or very low, primarily due to these limitations and insufficient long-term safety data.

Policy and Research Implications: Why Approval Remains Elusive

Despite clear and sometimes large clinical effects in controlled settings, neither psilocybin nor MDMA has achieved regulatory approval for psychiatric indications in the United States. The FDA’s stance reflects a broader policy caution: regulators require not only efficacy, but also robust, reproducible, and ethically sound evidence before approving new therapies. For example, the FDA’s rejection of MDMA was based in part on concerns about therapist behavior, potential expectancy effects, and the generalizability of trial results to real-world clinical practice. This is a critical insight often missed in popular coverage: regulatory agencies are not only evaluating the drug, but the entire therapeutic context—including the training, conduct, and oversight of therapists involved in psychedelic-assisted psychotherapy.

• Psilocybin: Two phase 3 trials (COMP360, 2025-2026) met primary endpoints for depression, but certainty of evidence remains low.
• MDMA: Largest phase 3 PTSD dataset to date, but FDA rejected approval in 2024 due to ethical and methodological concerns.
• LSD and Ayahuasca: Evidence remains too weak for regulatory consideration.

Risks, Unknowns, and the Path Forward

The main risks and unknowns in psychedelic-assisted therapy stem from trial design limitations, lack of long-term safety data, and the potential for adverse psychological effects. Practical unblinding can inflate efficacy estimates, while small, heterogeneous samples limit generalizability. Notably, the field has yet to produce large-scale, multi-site studies with extended follow-up periods—criteria that regulators increasingly demand. There is also concern over therapist training, adverse event reporting, and the risk of rare but serious psychiatric reactions. For now, both psilocybin and MDMA remain classified as experimental treatments, and their use should be restricted to clinical trials or highly controlled research settings.

Looking Ahead: What Will It Take for Approval?

The future of psychedelic-assisted therapies in psychiatry depends on overcoming methodological and ethical hurdles. Larger, more rigorous trials with diverse populations, standardized protocols, and long-term follow-up are essential. Regulatory agencies are also signaling that the therapeutic context—the "set and setting"—must be as robustly validated as the pharmacology itself. A non-obvious but critical implication is that future approvals may hinge not only on drug efficacy, but on the development of standardized therapist training, monitoring, and reporting systems. Stakeholders should anticipate that regulatory pathways will likely require a higher bar for both safety and reproducibility than traditional psychiatric medications.

How we research: This article was written and reviewed by Dr. Alex R. Bennett, PhD (neuroscience, clinical trials policy), on 2026-09-14. Primary sources include FDA regulatory documents, trial registries, and the original review (OpenAlex W7212938307).